1,376
Views
1
CrossRef citations to date
0
Altmetric
Research paper

Bacterial adhesion inhibitor prevents infection in a rodent surgical incision model

ORCID Icon, ORCID Icon, , , , , , ORCID Icon, , , , & ORCID Icon show all
Pages 695-706 | Received 20 Jun 2019, Accepted 10 Apr 2020, Published online: 03 Jun 2020

References

  • Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(Suppl 2):S66–88.
  • Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208.
  • Ban KA, Minei JP, Laronga C, et al. American college of surgeons and surgical infection society: surgical site infection guidelines, 2016 update. J Am Coll Surg. 2017;224:59–74.
  • Chopra I, Schofield C, Everett M, et al. Treatment of health-care-associated infections caused by gram-negative bacteria: a consensus statement. Lancet Infect Dis. 2008;8:133–139.
  • Oncul O, Öksüz S, Acar A, et al. Nosocomial infection characteristics in a burn intensive care unit: analysis of an eleven-year active surveillance. Burns. 2014;40:835–841.
  • Keen EF 3rd, Robinson BJ, Hospenthal DR, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns. 2010;36:819–825.
  • Keen EF 3rd, Robinson BJ, Hospenthal DR, et al. Incidence and bacteriology of burn infections at a military burn center. Burns. 2010;36:461–468.
  • Yun HC, Murray CK. Infection prevention in the deployed environment. US Army Med Dep J. 2016;(2–16):114–118.
  • Mirsalehian A, Feizabadi M, Nakhjavani FA, et al. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns. 2010;36:70–74.
  • Quick J, Cumley N, Wearn CM, et al. Seeking the source of seudomonas aeruginosa infections in a recently opened hospital: an observational study using whole-genome sequencing. BMJ Open. 2014;4:e006278.
  • Wurtz R, Karajovic M, Dacumos E, et al. Nosocomial infections in a burn intensive care unit. Burns. 1995;21:181–184.
  • Global A, Kluger Y, Ansaloni L. Declaration on appropriate use of antimicrobial agents across the surgical pathway. Surg Infect (Larchmt). 2017;18:846–853.
  • Cegelski L, Marshall GR, Eldridge GR, et al. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol. 2008;6:17–27.
  • Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.
  • Allen RC, Popat R, Diggle SP, et al. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014;12:300–308.
  • Muhlen S, Dersch P. Anti-virulence strategies to target bacterial infections. Curr Top Microbiol Immunol. 2016;398:147–183.
  • Spaulding CN, Klein RD, Ruer S, et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature. 2017;546:528–532.
  • Denis K, Le Bris M, Le Guennec L, et al. Targeting type IV pili as an antivirulence strategy against invasive meningococcal disease. Nat Microbiol. 2019;4:972–984.
  • Fleming D, Rumbaugh KP. Approaches to dispersing medical biofilms. Microorganisms. 2017;5:15.
  • Marshall NC, Finlay BB. Targeting the type III secretion system to treat bacterial infections. Expert Opin Ther Targets. 2014;18:137–152.
  • Francois B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit Care Med. 2012;40:2320–2326.
  • Farcasanu M, Wang AG, Uchański T, et al. Rapid discovery and characterization of synthetic neutralizing antibodies against anthrax edema toxin. Biochemistry. 2019;58:2996–3004.
  • Dumas EK, Gross T, Larabee J, et al. Anthrax vaccine precipitated induces edema toxin-neutralizing, edema factor-specific antibodies in human recipients. Clin Vaccine Immunol. 2017;24. DOI:https://doi.org/10.1128/CVI.00165-17.
  • Riddle MS, Kaminski RW, Di Paolo C, et al. Safety and Immunogenicity of a candidate bioconjugate vaccine against shigella flexneri 2A administered to healthy adults: a single-blind, randomized phase I study. Clin Vaccine Immunol. 2016;23:908–917.
  • Kong C, Neoh HM, Nathan S. Targeting staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins (Basel). 2016;8:72.
  • Krachler AM, Ham H, Orth K. Outer membrane adhesion factor multivalent adhesion molecule 7 initiates host cell binding during infection by gram-negative pathogens. Proc Natl Acad Sci U S A. 2011;108:11614–11619.
  • Stones DH, Al-Saedi F, Vaz D, et al. Biomimetic materials to characterize bacteria-host interactions. J Vis Exp. 2015. DOI:https://doi.org/10.3791/53400
  • Krachler AM, Orth K. Functional characterization of the interaction between bacterial adhesin multivalent adhesion molecule 7 (MAM7) protein and its host cell ligands. J Biol Chem. 2011;286:38939–38947.
  • Krachler AM, Mende K, Murray C, et al. In vitro characterization of multivalent adhesion molecule 7-based inhibition of multidrug-resistant bacteria isolated from wounded military personnel. Virulence. 2012;3:389–399.
  • Hawley CA, Watson CA, Orth K, et al. A MAM7 peptide-based inhibitor of staphylococcus aureus adhesion does not interfere with in vitro host cell function. PloS One. 2013;8:e81216.
  • Lim J, Stones DH, Hawley CA, et al. Multivalent adhesion molecule 7 clusters act as signaling platform for host cellular GTPase activation and facilitate epithelial barrier dysfunction. PLoS Pathog. 2014;10:e1004421.
  • Al-Saedi F, Stones DH, Vaz DP, et al. Displacement of pathogens by an engineered bacterium is a multi-factorial process that depends on attachment competition and interspecific antagonism. Infect Immun. 2016;84:1704–1711.
  • Huebinger RM, Stones DH, de Souza Santos M, et al. Targeting bacterial adherence inhibits multidrug-resistant pseudomonas aeruginosa infection following burn injury. Sci Rep. 2016;6:39341.
  • Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother. 2010;1:94–99.
  • Rupp ME, Ulphani JS, Fey PD, et al. Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. Infect Immun. 1999;67:2627–2632.
  • Kuklin NA, Pancari GD, Tobery TW, et al. Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models. Antimicrob Agents Chemother. 2003;47:2740–2748.
  • Francis KP, Yu J, Bellinger-Kawahara C, et al. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun. 2001;69:3350–3358.
  • Kadurugamuwa JL, Francis KP. Bioluminescent imaging of bacterial biofilm infections in vivo. Methods Mol Biol. 2008;431:225–239.
  • Wolf SE, Kauvar DS, Wade CE, et al. Comparison between civilian burns and combat burns from operation iraqi freedom and operation enduring freedom. Ann Surg. 2006;243:786–792. discussion 792-785.
  • Robson MC, Lea CE, Dalton JB, et al. Quantitative bacteriology and delayed wound closure. Surg Forum. 1968;19:501–502.
  • Robson MC, Heggers JP. Delayed wound closure based on bacterial counts. J Surg Oncol. 1970;2:379–383.
  • Zimmerli W, Waldvogel FA, Vaudaux P, et al. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis. 1982;146:487–497.
  • Krisp C, Jacobsen F, McKay MJ, et al. Proteome analysis reveals antiangiogenic environments in chronic wounds of diabetes mellitus type 2 patients. Proteomics. 2013;13:2670–2681.
  • Reiss MJ, Han Y-P, Garcia E, et al. Matrix metalloproteinase-9 delays wound healing in a murine wound model. Surgery. 2010;147:295–302.
  • Gao M, Nguyen TT, Suckow MA, et al. Acceleration of diabetic wound healing using a novel protease-anti-protease combination therapy. Proc Natl Acad Sci U S A. 2015;112:15226–15231.
  • Wang W, Yang C, Wang XY, et al. MicroRNA-129 and −335 promote diabetic wound healing by inhibiting Sp1-mediated MMP-9 expression. Diabetes. 2018;67:1627–1638.
  • Scalise A, Bianchi A, Tartaglione C, et al. Microenvironment and microbiology of skin wounds: the role of bacterial biofilms and related factors. Semin Vasc Surg. 2015;28:151–159.
  • Robson MC. Disturbances of wound healing. Ann Emerg Med. 1988;17:1274–1278.